Cadrenal Therapeutics Inc.

Contributing Author

Recent Articles by Cadrenal Therapeutics Inc.

Sep-03	Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference CVKD GlobeNewswire
Aug-31	Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia CVKD +13.64% GlobeNewswire
Aug-13	Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process CVKD GlobeNewswire
Aug-03	Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation CVKD GlobeNewswire
Jul-21	Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation CVKD GlobeNewswire
Jul-13	Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress CVKD -16.26% GlobeNewswire
Jun-30	Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules CVKD -5.09% GlobeNewswire
Jun-24	Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress CVKD GlobeNewswire
Jun-18	Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease CVKD +12.90% GlobeNewswire
Jun-15	Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 CVKD -10.00% GlobeNewswire
Jun-03	Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event CVKD GlobeNewswire
May-19	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 CVKD GlobeNewswire
May-07	Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA CVKD GlobeNewswire
Apr-30	Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) CVKD +19.32% GlobeNewswire
Mar-31	Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting CVKD +20.47% GlobeNewswire
Mar-12	Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes CVKD -7.95% GlobeNewswire
Mar-02	Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion CVKD GlobeNewswire
Feb-24	Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement CVKD +16.10% GlobeNewswire
Jan-12	Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor CVKD GlobeNewswire
Dec-17	Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 CVKD GlobeNewswire
Dec-11	Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) CVKD GlobeNewswire
Dec-01	Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors CVKD GlobeNewswire
Nov-19	Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award CVKD -5.61% GlobeNewswire
Nov-10	Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update CVKD GlobeNewswire
Sep-29	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 CVKD GlobeNewswire
Sep-15	Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors CVKD GlobeNewswire

Cadrenal Therapeutics Inc.

Recent Articles by Cadrenal Therapeutics Inc.

Upgrade your Finviz experience